I'm LongbridgeAI, I can summarize articles.Revenue: As of FY2026 Q2, the actual value is USD 1.708 M.
EPS: As of FY2026 Q2, the actual value is USD -0.04, beating the estimate of USD -0.05.
EBIT: As of FY2026 Q2, the actual value is USD -8.421 M.
Financial Results for the Three Months Ended June 30, 2026
Segment Revenue
Rani Therapeutics Holdings, Inc. reported $1.7 million in contract revenue for the three months ended June 30, 2026, which was an increase from no contract revenue in the same period of 2025, primarily due to a collaboration and license agreement with Chugai.
Operational Metrics
Research and Development Expenses decreased to $5.0 million for the three months ended June 30, 2026, from $5.5 million in the prior year period. General and Administrative Expenses increased to $5.5 million for the three months ended June 30, 2026, compared to $5.0 million in the prior year period. Loss from Operations improved to -$8.828 million for the three months ended June 30, 2026, from -$10.505 million in the same period of 2025. Interest Income and Other, Net, amounted to $0.415 million, up from $0.158 million in the prior year period. Interest Expense and Other, Net, significantly decreased to -$0.008 million from -$0.877 million in the prior year period. The Net Loss improved to -$8.421 million for the three months ended June 30, 2026, from -$11.224 million for the same period in 2025.
Financial Results for the Six Months Ended June 30, 2026
Segment Revenue
Contract revenue for the six months ended June 30, 2026, was $3.416 million, an increase from $0.172 million in the same period of 2025.
Operational Metrics
Research and Development Expenses were $10.178 million for the six months ended June 30, 2026, compared to $12.075 million in the prior year period. General and Administrative Expenses were $10.405 million for the six months ended June 30, 2026, compared to $10.615 million in the prior year period. The Net Loss improved to -$16.436 million for the six months ended June 30, 2026, from -$23.962 million for the same period in 2025.
Cash Position
As of June 30, 2026, Rani Therapeutics Holdings, Inc.’s cash, cash equivalents, and marketable securities totaled $53.4 million, an increase from $43.4 million as of March 31, 2026. The company completed a $20.0 million registered direct offering in May 2026.
Unique Metrics
Positive initial Phase 1a data for RT-114 showed oral bioavailability greater than 150% relative to matched subcutaneous dosing.
Outlook
Rani Therapeutics Holdings, Inc. expects additional data from the RT-114 Phase 1a expansion cohort by the end of 2026 and plans to initiate a Phase 1b repeat-dose study in patients with obesity by the end of 2026, with data anticipated in 2027. The company anticipates that its cash, cash equivalents, and marketable securities will be sufficient to fund operations at least through 2027. Furthermore, a collaboration with PegBio aims to advance the most promising candidates into clinical development.